JPRN-UMIN000042700已完成未知
A Multicenter, single-blind, randomized, parallel-group trial examing the Effectiveness of Precompression during Distal Pancreatectomy. - HiSCO-10 trial
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.patients with severe ischemic heart disease(NYHA > III) 2.patients with grade C liver damage 3.patients required continuous oxygen administration due to severe lung disease 4.patients who received dialysis 5.patients with active cancer disease that may influence perioperative adverse events. 6.Patients who enable to enroll in this trial due to their mental illness. 7.Patients who reject to enroll in this trial
研究者
相似试验
已完成
不适用
A Multicenter, single-blind, randomized, parallel-group trial comparing Reinforced Reload with Tri-Staple with Tri-Staple during Distal PancreatectomyPatients who underwent distal pancreatectomyJPRN-UMIN000022341Hiroshima University Hospital120
招募中
2 期
A Multicenter, single-blind, randomized, parallel-group trial comparing stapler closure with Clip on Staple method with stapler closure alone during Distal PancreatectomyPatients who undergo distal pancreatectomyJPRN-UMIN000042217Kyushu Study group of Clinical Cancer (KSCC)188
招募中
1 期
A multicentre, randomized, single-blind, parallel-controlled study of acupoint catgut embedding for metabolic fatty liver diseaseITMCTR2100004943Shuguang Hospital affiliated to Shanghai Universtiy of Traditonal Chinese Medicine
未知
2 期
Kagami/SDS ProjectGastrointestinal Endoscopic Tests (Including Endoscopic Polypectomy)JPRN-jRCT2080221299AstraZeneca
进行中（未招募）
1 期
Study of efficacy, safety and tolerability data for BAF312 compared to placebo in patients with secondary progressive multiple sclerosis followed by extended treatment with open-label BAF312Secondary progressive multiple sclerosisMedDRA version: 21.1Level: PTClassification code 10063400Term: Secondary progressive multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2012-003056-36-GBovartis Pharma Services AG1,530